Current stock page

Financial Data

AXSM Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

AXSMAxsome Therapeutics, Inc.

Healthcare / Biotechnology

Low Priority

Relative Laggard

BearishEdge 3/10
$141.69−$2.68 (−1.86%)

Latest quote

  • Momentum
    24
  • Value
    65
  • Quality
    57
  • Risk resilience
    57
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$259.69M$218.38M$191.2M$196M$170.99M$150.04M$121.46M$118.77M
Gross Profit$241.89M$204.81M$176.48M$183.67M$159.08M$136.59M$111.67M$108.25M
Operating Income-$11.07M-$49.65M-$63.36M-$29.43M-$46.11M-$36.71M-$56.98M-$72.62M
Net Income-$12.88M-$51.31M-$64.54M-$28.56M-$47.23M-$47.97M-$59.41M-$74.91M
EPS-$0.25-$0.99-$1.26-$0.56-$0.94-$0.97-$1.22-$1.54
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$9.47M-$32.95M-$20.7M-$18.65M$1.05M-$32.42M-$43.38M-$26.2M
Capital Expenditure-$197K-$450K-$121K-$71K-$58K-$13K-$338K-$30K
Free Cash Flow-$9.67M-$33.4M-$20.82M-$18.72M$988K-$32.44M-$43.71M-$26.23M
Net Cash Provided By Operating Activities-$9.47M-$32.95M-$20.7M-$18.65M$1.05M-$32.42M-$43.38M-$26.2M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$826.77M$761.45M$713.61M$689.81M$669.25M$639.79M$596.67M$568.5M
Total Debt$218.67M$219.21M$219.9M$241.3M$218.6M$217.31M$211.23M$192.96M
Cash And Cash Equivalents$313.86M$319.85M$305.11M$322.93M$325.27M$303.02M$300.91M$315.35M
Total Liabilities$721.34M$678.14M$659.02M$601.51M$595.52M$566.71M$543.47M$511.48M
Total Stockholders Equity$105.43M$83.3M$54.59M$88.3M$73.73M$73.08M$53.21M$57.02M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio64.57136.56209.81100.2192.172.08107109.05
P/S ratio8.59———————
Debt To Equity2.072.634.032.732.962.973.973.38
Free Cash Flow Yield-1.21%-0.63%-0.62%-1.06%-1.49%-2.29%-2.08%-2.07%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio64.57136.56209.81100.2192.172.08107109.05
P/S ratio8.59———————
Return On Equity-149.19%-230.05%-3.45%-207.46%-3.11%-3.38%-5.23%-5.04%
Debt To Equity2.072.634.032.732.962.973.973.38

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-46.3x
Pb70.48x
Revenue Growth Yoy51.87%
EPS Growth Yoy73.40%
Gross Margin93.25%
Operating Margin-17.74%
ROE-189.73%
ROIC-39.59%
Debt To Equity2.07
FCF Yield-1.11%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$141.69
Volume973,068
RSI (14)40.79
MACD-8.3
MACD signal-10.65
MACD histogram2.35
ADX (14)37.21
SMA (50)$171.45
SMA (200)$197.05
ATR (14)$7.81
Historical volatility (annualized)53.18%
Volume (20-day average)1.14M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score57/100
Beta0.66
Annual volatility45.79%
Max Drawdown-49.13%
Sharpe Ratio0.2
VaR (95%, 1-day)-4.07%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

AXSM Financial Data FAQ

What is Axsome Therapeutics, Inc.'s revenue?

Axsome Therapeutics, Inc.'s revenue is one of the core financial data points for AXSM. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Axsome Therapeutics, Inc.'s revenue growing?

Revenue growth shows whether Axsome Therapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is AXSM's EPS?

AXSM's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Axsome Therapeutics, Inc.'s net income?

Axsome Therapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Axsome Therapeutics, Inc. generate?

Free cash flow shows how much cash Axsome Therapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Axsome Therapeutics, Inc. have?

Cash and debt help frame AXSM's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.